These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24576791)

  • 1. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception.
    Trussell J; Hassan F; Henry N; Pocoski J; Law A; Filonenko A
    Contraception; 2014 May; 89(5):451-9. PubMed ID: 24576791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg versus other long-acting reversible contraceptives for contraception in Spain.
    Conde JCQ; Parra Ribes I; Perelló-Capo J; Lobo Abascal P; García IC; Andeyro García M; Gutiérrez Alés J; Herrero Conde M; Rius Tarruella J; Espinós Lafuente B
    Eur J Contracept Reprod Health Care; 2024 Oct; 29(5):224-232. PubMed ID: 38989683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving cost-neutrality with long-acting reversible contraceptive methods.
    Trussell J; Hassan F; Lowin J; Law A; Filonenko A
    Contraception; 2015 Jan; 91(1):49-56. PubMed ID: 25282161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years.
    Nelson AL
    Expert Opin Drug Deliv; 2017 Sep; 14(9):1131-1140. PubMed ID: 28696796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding Access to a New, More Affordable Levonorgestrel Intrauterine System in Kenya: Service Delivery Costs Compared With Other Contraceptive Methods and Perspectives of Key Opinion Leaders.
    Rademacher KH; Solomon M; Brett T; Bratt JH; Pascual C; Njunguru J; Steiner MJ
    Glob Health Sci Pract; 2016 Aug; 4 Suppl 2(Suppl 2):S83-93. PubMed ID: 27540128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of a low-dose contraceptive levonorgestrel intrauterine system in Sweden.
    Henry N; Hawes C; Lowin J; Lekander I; Filonenko A; Kallner HK
    Acta Obstet Gynecol Scand; 2015 Aug; 94(8):884-90. PubMed ID: 26015090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
    Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
    Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary prescriptions pattern of different dose levonorgestrel-releasing intrauterine systems in an Italian service for family planning.
    Grandi G; De Fata R; Varliero F; Del Savio MC; Facchinetti F
    Gynecol Endocrinol; 2020 Dec; 36(12):1086-1089. PubMed ID: 32748655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial.
    Gupta JK; Daniels JP; Middleton LJ; Pattison HM; Prileszky G; Roberts TE; Sanghera S; Barton P; Gray R; Kai J;
    Health Technol Assess; 2015 Oct; 19(88):i-xxv, 1-118. PubMed ID: 26507206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of the levonorgestrel-releasing intrauterine system for the treatment of idiopathic heavy menstrual bleeding in the United States.
    Ganz ML; Shah D; Gidwani R; Filonenko A; Su W; Pocoski J; Law A
    Value Health; 2013; 16(2):325-33. PubMed ID: 23538185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy.
    Caruso S; Cianci S; Vitale SG; Fava V; Cutello S; Cianci A
    Eur J Contracept Reprod Health Care; 2018 Feb; 23(1):24-31. PubMed ID: 29436865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences with the levonorgestrel-releasing intrauterine system in Kenya: qualitative interviews with users and their partners.
    Nanda G; Rademacher K; Solomon M; Mercer S; Wawire J; Ngahu R
    Eur J Contracept Reprod Health Care; 2018 Aug; 23(4):303-308. PubMed ID: 30198796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal and intrauterine methods for contraception for women aged 25 years and younger.
    Krashin J; Tang JH; Mody S; Lopez LM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD009805. PubMed ID: 26280888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.
    Nelson AL
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):833-842. PubMed ID: 28617060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
    Mittermeier T; Farrant C; Wise MR
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception.
    Mansour D
    Contraception; 2012 Mar; 85(3):224-34. PubMed ID: 22067761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
    Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
    Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of emergency contraception options over 1 year.
    Bellows BK; Tak CR; Sanders JN; Turok DK; Schwarz EB
    Am J Obstet Gynecol; 2018 May; 218(5):508.e1-508.e9. PubMed ID: 29409847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levonorgestrel-releasing intrauterine system vs. usual medical treatment for menorrhagia: an economic evaluation alongside a randomised controlled trial.
    Sanghera S; Roberts TE; Barton P; Frew E; Daniels J; Middleton L; Gennard L; Kai J; Gupta JK
    PLoS One; 2014; 9(3):e91891. PubMed ID: 24638071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.